• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球范围内的血色素沉着病和献血政策:血液服务机构的调查。

Worldwide policies on haemochromatosis and blood donation: a survey among blood services.

机构信息

Centre for Evidence-Based Practice, Belgian Red Cross-Flanders, Mechelen, Belgium.

出版信息

Vox Sang. 2013 Aug;105(2):121-8. doi: 10.1111/vox.12038. Epub 2013 May 11.

DOI:10.1111/vox.12038
PMID:23663183
Abstract

BACKGROUND AND OBJECTIVES

Haemochromatosis (HC) is a disorder of iron metabolism, requiring frequent phlebotomy to normalize high serum iron levels. There is currently no consensus relating to the eligibility of these patients to donate blood for transfusion. To gain a better understanding of the policies worldwide, a survey amongst blood services was performed.

MATERIALS AND METHODS

A web-based questionnaire was developed and distributed among 44 blood services in 41 countries to identify the different policies relating to patients with HC and blood donation.

RESULTS

Respondents from 35 blood services (80%) of 33 countries completed the questionnaire. In 24 blood services among them (69%), individuals with genetic susceptibility for HC and/or patients with HC are accepted as blood donors. In approximately one-third of these blood centres (33%), genetic carriers/patients are allowed to donate blood more frequently than regular donors. Prescription from/approval by the patient's treating physician and/or a donor physician is required in the majority of the blood services (87%). Similar policies were identified in a few countries; however, in general, the policies regarding blood donation from patients with HC remain widely variable.

CONCLUSION

The results of our survey demonstrate large differences in the blood donation policies regarding carriers/patients with HC illustrating the need for uniform evidence-based and cost-effective policies which could benefit both HC patients and the blood supply around the world.

摘要

背景与目的

血色病(HC)是一种铁代谢紊乱,需要频繁放血以将血清铁水平恢复正常。目前,对于这些患者是否有资格献血用于输血,尚无共识。为了更好地了解全球的政策,我们对血液服务机构进行了调查。

材料与方法

我们开发了一个基于网络的问卷,并分发给 41 个国家的 44 个血液服务机构,以确定与 HC 患者和献血相关的不同政策。

结果

来自 33 个国家的 35 个血液服务机构(80%)的受访者完成了问卷。在其中 24 个血液中心(69%)中,遗传易感性 HC 个体和/或 HC 患者被接受为献血者。在这些血液中心的大约三分之一(33%)中,遗传携带者/患者允许比常规献血者更频繁地献血。大多数血液服务机构(87%)需要患者治疗医生的处方/批准和/或献血医生的批准。在少数几个国家也确定了类似的政策;然而,总的来说,关于 HC 患者献血的政策仍然存在很大差异。

结论

我们的调查结果表明,HC 携带者/患者的献血政策存在很大差异,这表明需要制定统一的、基于证据的、具有成本效益的政策,这将使 HC 患者和世界各地的血液供应都受益。

相似文献

1
Worldwide policies on haemochromatosis and blood donation: a survey among blood services.全球范围内的血色素沉着病和献血政策:血液服务机构的调查。
Vox Sang. 2013 Aug;105(2):121-8. doi: 10.1111/vox.12038. Epub 2013 May 11.
2
Facilitation of blood donation amongst haemochromatosis patients.促进血色素沉着症患者献血。
Transfus Med. 2015 Aug;25(4):239-42. doi: 10.1111/tme.12182. Epub 2015 Mar 19.
3
Phlebotomy patterns in haemochromatosis patients and their contribution to the blood supply.血色素沉着症患者的放血模式及其对血液供应的贡献。
N Z Med J. 2012 Jul 29;125(1358):29-34.
4
Blood donation by healthy individuals with haemochromatosis.患有血色素沉着症的健康个体献血。
N Z Med J. 2000 Mar 10;113(1105):77-8.
5
Worldwide policies on epilepsy and blood donation: a survey among blood services.全球癫痫与献血政策:血液服务机构调查
Vox Sang. 2018 Feb;113(2):104-109. doi: 10.1111/vox.12618. Epub 2018 Jan 4.
6
Iron and blood donation- an under-recognised safety issue.铁与献血——一个未得到充分认识的安全问题。
Dev Biol (Basel). 2007;127:137-46.
7
Hemochromatosis patients as voluntary blood donors.血色素沉着症患者作为自愿献血者。
Can J Gastroenterol. 2004 Jun;18(6):393-6. doi: 10.1155/2004/767529.
8
Demanding pure motives for donation: the moral acceptability of blood donations by haemochromatosis patients.苛求献血的纯粹动机:血色素沉着症患者献血的道德可接受性
J Med Ethics. 2005 Feb;31(2):69-72. doi: 10.1136/jme.2002.001271.
9
Haemochromatosis: evaluating the effectiveness of a novel patient self-management approach to venesection as blood donation.血色素沉着症:评估一种新型患者自我管理的静脉切开放血献血方法的有效性。
N Z Med J. 2017 Jun 16;130(1457):26-33.
10
Cost-effectiveness of FDA variance for blood collection from individuals with hereditary hemochromatosis at a 398-bed hospital-based donor center.在一家拥有398张床位的医院供血中心,针对遗传性血色素沉着症患者采血的美国食品药品监督管理局(FDA)差异的成本效益分析
Immunohematology. 2009;25(4):170-3.

引用本文的文献

1
Exploring the experiences of hemochromatosis (HHC) patients who undergo therapeutic venesection at a blood collection agency.探索在采血机构接受治疗性静脉放血的血色素沉着症(HHC)患者的经历。
Transfusion. 2025 Mar;65(3):531-538. doi: 10.1111/trf.18153. Epub 2025 Feb 12.
2
Blood donation for iron removal in individuals with HFE mutations: study of efficacy and safety and short review on hemochromatosis and blood donation.针对具有HFE基因突变个体进行的用于铁清除的献血:疗效与安全性研究以及关于血色素沉着症和献血的简短综述
Front Med (Lausanne). 2024 Mar 19;11:1362941. doi: 10.3389/fmed.2024.1362941. eCollection 2024.
3
Transfusion of red cells from donors with hereditary haemochromatosis improve haemoglobin increments in patients.
输注来自遗传性血色素沉着症供者的红细胞可提高患者的血红蛋白增量。
Br J Haematol. 2023 Sep;202(5):1052-1054. doi: 10.1111/bjh.18951. Epub 2023 Jul 17.
4
Current Understanding of the Relationship between Blood Donor Variability and Blood Component Quality.当前对献血者变异性与血液成分质量之间关系的认识。
Int J Mol Sci. 2021 Apr 11;22(8):3943. doi: 10.3390/ijms22083943.